Skip to content

Bevacizumab for Primary Pterygium Treatment

Conjunctival Autografting Alone or Combined With Subconjunctival Bevacizumab for Primary Pterygium Treatment.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01686529
Enrollment
49
Registered
2012-09-18
Start date
2010-03-31
Completion date
2012-02-29
Last updated
2013-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium

Keywords

Pterygium, bevacizumab, autoconjunctival graft

Brief summary

The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.

Interventions

PROCEDUREAutoconjunctival grafting

The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.

DRUGSubconjuntival bevacizumab injection

The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.

Sponsors

Instituto de Oftalmología Fundación Conde de Valenciana
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with primary pterygium

Exclusion criteria

* Patients with diabetes mellitus * collagenopathies, * previous ocular surgeries, * pregnant or lactating patients

Design outcomes

Primary

MeasureTime frameDescription
Pterygium recurrenceOne point.The pterygium recurrence is evaluated at one year postoperative

Secondary

MeasureTime frameDescription
Conjunctival ischemiaIschemia is measured at 24 h, 1 week, 15 days, six months and one year postoperativeWhiteness of conjunctival bed, that means absence of blood vessels

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026